375 related articles for article (PubMed ID: 29878866)
21. Safety and outcomes of
Lin E; Chen T; Little A; Holliday L; Roach P; Butler P; Hosking E; Bailey E; Elison B; Currow D
Intern Med J; 2019 Oct; 49(10):1268-1277. PubMed ID: 31062490
[TBL] [Abstract][Full Text] [Related]
22. Safety and Efficacy of 177 Lu-DOTATATE in Neuroendocrine Tumor Patients With Extensive Bone Disease.
Alsadik S; Gnanasegaran G; Chen L; Quigley AM; Mandair D; Toumpanakis C; Caplin M; Navalkissoor S
Clin Nucl Med; 2023 Aug; 48(8):667-672. PubMed ID: 37167406
[TBL] [Abstract][Full Text] [Related]
23. High clinical and morphologic response using
Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
[TBL] [Abstract][Full Text] [Related]
24. Guidance on
Abbott A; Sakellis CG; Andersen E; Kuzuhara Y; Gilbert L; Boyle K; Kulke MH; Chan JA; Jacene HA; Van den Abbeele AD
J Nucl Med Technol; 2018 Sep; 46(3):237-244. PubMed ID: 30076245
[No Abstract] [Full Text] [Related]
25. Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
Teunissen JJ; Kwekkeboom DJ; Krenning EP
J Clin Oncol; 2004 Jul; 22(13):2724-9. PubMed ID: 15226340
[TBL] [Abstract][Full Text] [Related]
26. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Efficacy, Survival, and Safety of [
Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
[No Abstract] [Full Text] [Related]
28. NETTER-1 Phase III in Patients With Midgut Neuroendocrine Tumors Treated With 177Lu-DOTATATE: Efficacy and Safety Results.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):8-9. PubMed ID: 27168104
[No Abstract] [Full Text] [Related]
29. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
Ranade R; Basu S
J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
[TBL] [Abstract][Full Text] [Related]
30. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
[TBL] [Abstract][Full Text] [Related]
31. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of
Clement D; Navalkissoor S; Srirajaskanthan R; Courbon F; Dierickx L; Eccles A; Lewington V; Mitjavila M; Percovich JC; Lequoy B; He B; Folitar I; Ramage J
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3529-3537. PubMed ID: 35389069
[TBL] [Abstract][Full Text] [Related]
33. Estimation of Health-Related Utilities for
Soare IA; Leeuwenkamp O; Longworth L
Pharmacoecon Open; 2021 Dec; 5(4):715-725. PubMed ID: 34260017
[TBL] [Abstract][Full Text] [Related]
34. Early efficacy of and toxicity from lutetium-177-DOTATATE treatment in patients with progressive metastatic NET.
Pencharz D; Walker M; Yalchin M; Quigley AM; Caplin M; Toumpanakis C; Navalkissoor S
Nucl Med Commun; 2017 Jul; 38(7):593-600. PubMed ID: 28471845
[TBL] [Abstract][Full Text] [Related]
35. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
[TBL] [Abstract][Full Text] [Related]
36.
Hervás I; Bello P; Falgas M; Del Olmo MI; Torres I; Olivas C; Vera V; Oliván P; Yepes AM
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):91-98. PubMed ID: 27889527
[TBL] [Abstract][Full Text] [Related]
37. Twins in spirit part IV - [
Brogsitter C; Hartmann H; Wunderlich G; Schottelius M; Wester HJ; Kotzerke J
Nuklearmedizin; 2017 Feb; 56(1):1-8. PubMed ID: 28138688
[TBL] [Abstract][Full Text] [Related]
38. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with
Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L
Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of radiolabelled somatostatin analogues (
Medina-Ornelas SS; García-Pérez FO
Rev Esp Med Nucl Imagen Mol; 2017; 36(3):166-174. PubMed ID: 27890514
[TBL] [Abstract][Full Text] [Related]
40. [Neuroendocrine tumor therapy (NETTER-1) trial:
Derlin T
Radiologe; 2017 May; 57(5):343-345. PubMed ID: 28184947
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]